strate for DNA-mediated enzymatic processes in the nucleus-is a platform that instills stringent regulation on nuclear processes, such as transcription. Much of the regulation imposed by chromatin is achieved through the histone code-myriad covalent modifications placed on histones at particular loci to specify a functional outcome (Jenuwein and Allis, 2001) . A theme of the histone code is that specific histone modifications are determined by local levels and activities of opposing enzyme pairs such as histone acetyltransferases and histone deacetylases (Jenuwein and Allis, 2001) . Even histone methylation, which was thought to be an irreversible epigenetic mark, can be reversed by histone demethylases, including lysine-specific demethylase 1 (LSD1) and a family of JmjC domain-containing histone demethylases (such as JMJD1A) (Shi and Whetstine, 2007) . LSD1 was originally identified as a component of the CoREST corepressor complex and, in this context, it demethylates dimethyl lysine 4 of histone H3 (H3-K4me2) in vitro (Lee et al., 2005; Shi et al., 2005) . H3-K4me2 is associated with an activated transcriptional state and, therefore, demethylation of this mark by LSD1 is associated with repression of CoREST target genes (Shi et al., 2004) . In addition to its role as a corepressor, LSD1 is also a coactivator of the androgen receptor, where its presence at target promoters in cells correlates with the demethylation of H3-K9me2 (Metzger et al., 2005) . H3-K9me2 is associated with repressed genes, and, thus, its demethylation correlates with a positive effect on target gene transcription (Daniel et al., 2005; Shi and Whetstine, 2007) .
In this issue, Garcia-Bassets et al. (2007) examine the role of histone lysine methylation, a cohort of histone methyltransferases, and LSD1 in establishing ligand dependency for gene activation by estrogen receptor α (ERα). Their starting point was a seemingly simple question: what sites does LSD1 bind to in ERα-positive MCF-7 human breast-cancer cells treated with estradiol? The answer they obtained was surprising.
For their LSD1 genomic localization studies, Garcia-Bassets et al. (2007) used a variation of genomewide chromatin immunoprecipitation (ChIP) called ChIP-DSL (DNA selection and ligation). ChIP-DSL is more sensitive than conventional ChIPchip technology, yielding an impressive number of binding targets (see below), but, due to practical considerations, is also likely to have a more limited resolution for determining precise genomic localization. With ChIP-DSL, crosslinked and immunoprecipitated genomic DNA serves as a template to direct the precise sequence-specific ligation of a library of 20-mer oligonucleotide pairs. The ligated oligonucleotide library is amplified, labeled, and used to hybridize a DNA microarray containing spotted 40-mer probes corresponding to each possible correctly ligated 20-mer pair in the library. A signal for a specific probe on the microarray requires the presence of the corresponding target in the immunoprecipitated genomic DNA .
Using ChIP-DSL, the authors found that ?4,200 out of the ?20,000 promoters they queried were occupied by LSD1. Furthermore, ?80% of the LSD1-positive promoters were also occupied by RNA polymerase II, with the corresponding genes showing detectable expression. In total, the authors found more active genes associated with LSD1 than inactive genes by a ratio of 4:1. Thus, in addition to its previously characterized role in transcriptional repression (Shi and Whetstine, 2007) , LSD1 has an even broader role in transcriptional activation. In additional ChIP-DSL experiments , the authors identified ? 580 ERα-positive promoters in the presence of estradiol (compared to 153 ERα-positive promoters identified in a previous study using conventional ChIP-chip technology with an ?18,700 human promoter array [Laganiere et al., 2005] ). Of the ? 580 ERα-positive promoters, ? 60% were LSD1-positive as well, suggesting a surprisingly broad requirement for LSD1 at estrogenregulated promoters.
To explore the role of LSD1 in ERα-mediated gene expression in more detail, the authors performed a variety of cell-based gene-specific assays. RNAi-mediated knockdown of LSD1 was shown to inhibit estradiol-
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In this issue, Garcia-Bassets et al. (2007) show that spurious transcriptional activation by unliganded nuclear receptors is inhibited by histone lysine methylation. This inhibitory histone modification code is efficiently countered by the ligand-dependent recruitment of histone lysine demethylases, including lysine-specific demethylase 1 (LSD1), which appear to be used for this purpose by a number of signal-regulated transcriptional activators.
dependent expression of LSD1-positive (e.g., TFF1 and GREB1), but not LSD1-negative (e.g., WISP), ERα target genes. In complementation studies, wild-type, but not enzymatically inactive LSD1, was able to restore estradiol-dependent expression of the LSD1-positive genes. Interestingly, a reduction in both H3-K4me2 and H3-K9me2 was observed concomitant with the estradiol-dependent recruitment of ERα and LSD1 to these target genes. Together, these assays indicate a key role for LSD1 in the estradiol-dependent expression of ERα target genes. Next, the authors examined the role of histone methyltransferases that lay down the methylated histone marks. Although RNAi-mediated depletion of known H3-K4 histone methyltransferases (e.g., MLL1) had little effect on the basal expression of TFF1 and GREB1, depletion of several H3-K9 histone methyltransferases (e.g., RIZ1, ESET, and EuHMTase1) derepressed the promoters. This occurred in the absence of ligand but was dependent on the recruitment of unliganded ERα to the promoters. As expected, in unmanipulated cells, the binding of ESET and RIZ1 at the TFF1 and GREB1 promoters was reduced upon treatment with estradiol, corresponding to the reduction in H3 methylation and recruitment of ERα and LSD1 noted above.
Collectively, the results presented by Garcia-Bassets et al. (2007) suggest a carefully orchestrated mechanism for preventing spurious transcriptional activation by unliganded nuclear receptors and allowing appropriate activation in the presence of ligand. The mechanism involves (1) the establishment of inhibitory histone methylation marks by specific histone methyltransferases, which act to keep target promoters repressed in the absence of ligand in part by blocking the binding of unliganded receptor (a "gatekeeper" function) and (2) the reversal of these inhibitory marks by the ligand-dependent recruitment of LSD1 to DNA bound receptor. These histone-modifying enzymes appear to play a similar role for other signal-regulated transcription systems (such as those controlled by androgen receptor, retinoic acid receptor β, NF-κB, and AP-1). Interestingly, LSD1-negative estradiol-regulated genes, such as WISP2, use a similar mechanism, but with a different histone methyltransferase/histone demethylase pair (i.e., G9a and JMJD1A). Thus, this mode of regulation is likely to represent a fundamental mechanism controlling the regulation of a wide array of signal-regulated genes.
Most prior studies of LSD1 have examined its role as an H3-K4me2 demethylating corepressor (Shi and Whetstine, 2007) . The results from Garcia-Bassets et al. (2007) indicating a broad role for LSD1 in counteracting the repressive effects of H3-K9 histone methyltransferases pose several important mechanistic questions. For example, how is the substrate specificity of LSD1 altered from that of an H3-K4 demethylase at negatively regulated CoREST target genes to an H3-K9 demethylase at positively regulated LSD1 target genes? Perhaps an LSD1-interacting coregulator, the transcription factors that recruit LSD1, or other localized histone marks allosterically modify the substrate specificity of the enzyme, as suggested by previous studies (Lee et al., 2005; Metzger et al., 2005; Shi and Whetstine, 2007; Shi et al., 2005) .
Additionally, what is the mechanism by which the H3-K9me2 mark is transduced into a signal that prevents the inappropriate activation of transcriptional targets by unstimulated transcription factors? Acetylation and methylation of a particular lysine are mutually exclusive (Jenuwein and Allis, 2001) . Perhaps the role of H3-K9me2 in transcriptional repression is a manifestation of a crucial positive role of H3-K9 acetylation in signal-regulated transcription. Or, perhaps H3-K9me2 serves as a binding platform for a corepressive effector protein, such as heterochromatin protein 1 (HP1). HP1, known to bind the heterochromatin-specific mark H3-K9me3, has also been shown to associate with H3-K9me2, a mark specifically involved in the repression of euchromatic genes (Daniel et al., 2005) . Alternatively, demethylation of nonhistone targets (e.g., transcription factors or coregulators) by LSD1 may be the actual activating signal or function as an alternate signal. Proving a causative role for a particular histone modification is a difficult task. A promising approach is the use of in vitro chromatin assembly and transcription systems together containing mutant or uniformly modified histones . Such an approach will be instrumental in addressing these questions.
Although many questions remain, there is little doubt that the results from Garcia-Bassets et al. (2007) represent a large step forward in our understanding of how opposing enzyme pairs work together to provide stringent regulation of signalregulated transcription.
